Anastrozole

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Anastrozole

Aromatase inhibitor, recorded alongside testosterone protocols where oestradiol management is part of the plan.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Anastrozole is an FDA-approved aromatase inhibitor for hormone receptor-positive breast cancer in postmenopausal women, used as adjuvant treatment, first-line treatment of advanced disease, and after tamoxifen. It blocks aromatase, the enzyme that makes oestrogen from androgens. The label warns about more ischaemic cardiac events in women with existing heart disease, falls in bone mineral density and rises in total cholesterol. It is contraindicated before menopause and in pregnancy. This is regulator-approved labelling.

Benefits reported in the imported source

• Hormone receptor-positive breast cancer in postmenopausal women.
• Adjuvant treatment, as first-line treatment of advanced disease, and after tamoxifen.
• Blocks the enzyme that makes oestrogen from androgens

Risks and limits

• The label warns of more ischaemic cardiac events in women with existing heart disease
• Bone mineral density falls and total cholesterol rises
• Contraindicated before menopause and in pregnancy; the best adjuvant duration is unknown

Source bottom line: An approved breast cancer medicine whose label flags cardiac events, bone loss and higher cholesterol.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 50 hours. FDA label, Arimidex Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Arimidex (anastrozole) tablet FDA Label
• Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors (Kim 2026)
• Anastrozole tablets prescribing information (DailyMed)
• DailyMed: anastrozole